vision loss with tirzepatide Can GLP-1 Drugs Cause Loss? What the Research Says Ophthalmic complications observed in patients

Confirmed for 2026 Health New England Dropping Coverage Starting January 1, 2026 , Health New England will no longer cover Zepbound, Saxenda, or Wegovy for Individual and Small Group members

Tirzepatide reduces it disproportionately which is why the metabolic improvements seen in the SURPASS diabetes trials, including HbA1c reductions of 2.02.3%, were among the largest ever documented for any antidiabetic medication

The decision to start semaglutide therapy isn't based on hitting a specific weight milestoneit depends on your body mass index (BMI), existing weight-related health conditions, and metabolic readiness

In certain cases, providers may consider combination protocols

GHK-Cu ,

The SOUL trial compared oral semaglutide to placebo as an adjunct to the standard of care to prevent major adverse cardiovascular events (MACE), such as cardiac arrest, stroke, heart failure, or cardiovascular death